Sagimet Biosciences Inc. Reclassifications of Temporary to Permanent Equity
Sagimet Biosciences Inc. (SGMT) reported Reclassifications of Temporary to Permanent Equity of $214.62 million for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-12.
Financial Statements › Shareholders' Equity
us-gaap:ReclassificationsOfTemporaryToPermanentEquity · last filed 2025-03-12
- Sagimet Biosciences Inc. reclassifications of temporary to permanent equity for the quarter ending 2023-09-30 was $214.62M.
- Sagimet Biosciences Inc. reclassifications of temporary to permanent equity for fiscal 2023 was $214.62M.
| Period end | Reclassifications of Temporary to Permanent Equity 3 month | Reclassifications of Temporary to Permanent Equity 12 month |
|---|---|---|
| 2023-12-31 | $214.62M 10-K · filed 2025-03-12 | |
| 2023-09-30 | $214.62M 10-Q · filed 2024-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |